Identification and characterization of novel therapeutic targets and biomarkers in chronic myeloid leukemia

Chronic myeloid leukemia (CML) has long served as a paradigm for new insights into the cellular origin, pathogenesis and treatment of human cancers. ABL tyrosine kinase inhibitor (TKI) therapies have had remarkable effects on treatment of early phase CML. However, TKI monotherapies are not curative,...

Full description

Bibliographic Details
Main Author: Lin, Hanyang
Language:English
Published: University of British Columbia 2016
Online Access:http://hdl.handle.net/2429/58470

Similar Items